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Although it is a leader in many fields of stem cell research, Japan’s policies on many areas of stem cell
research have not been widely reported or analyzed in the international literature. In this report, we provide
an overview of Japan’s centralized approach to regulation and analyze its policy implementation.Recent years have seen significant
achievements in the fields of stem cell
research and developmental engineer-
ing with clear clinical implications and
which have contributed to the tremen-
dous expectations surrounding the stem
cell applications worldwide. This sense
of anticipation has been accompanied,
however, by debates over the ethical,
social, and legal issues concomitant with
the use of human embryonic pluripotent
cells, making it necessary for scientists
and other stakeholders in many countries
to confront a range of issues extending
beyond the laboratory. Such issues have
been particularly problematic for scien-
tists working, or seeking to work, with
human embryonic stem cells (hESCs) or
somatic cell nuclear transfer (SCNT) in
many countries. Governments at both
the national and state levels adopted
variousmeans of addressing these ethical
tensions and of developing frameworks
for the regulation of basic and clinical
research with such cells. Similarly, the
concept of somatic cell nuclear trans-
fer using human blastocysts and nuclei
generated controversy on a global scale,
igniting extensive and frequently pro-
tracted debate and legislative efforts on
a global scale.
The Japanese government, however,
took an early and proactive stance on
addressing ethical, legal, and social
aspects of research involving human stem
cells and embryos (Kato, 2005), resulting
in the establishment of binding guidelines
on fundamental research that, at least
superficially, placed Japan among the
group of nations noted for their ‘‘permis-sive’’ or ‘‘research-friendly’’ policies.
A closer look, however, reveals that
although the Japanese governmental
bureaucracy did initiate early regulatory
actions on the derivation and use of
human embryonic stem cells, the manner
in which thesewere developed and imple-
mented may have actually worked to
hinder several areas of human stem cell
research in Japan up to the present day.
Regulation of Human SCNT
Soon after reports of the cloning of
mammals such as sheep and mice from
somatic cells, Japan began to develop
policies to address the possibility of
performing SCNT with human cells or
genetic material. In 1999, a subcommittee
of the cabinet Council on Science and
Technology (CST) presented the Prime
Minister with a report on techniques that
would potentially enable human repro-
ductive cloning. Based on this subcom-
mittee’s recommendations, the National
Diet (Japan’s parliamentary body)
enacted the ‘‘Law concerning regulation
of human cloning techniques and other
similar techniques’’ in 2001 (National
Diet, 2001), one of the first laws in any
country to expressly prohibit human
reproductive cloning in any country.
The new law did not, however, address
legal issues surrounding the generation of
research-use human embryos by somatic
cell nuclear transfer. An expert panel was
convened and met more than 20 times
over the next 3 years (during which period
a moratorium was imposed on the crea-
tion of human embryos for research pur-
poses via SCNT) before concluding thatCell Stem Cthe creation of human embryos should
be permitted, but only for research into
intractable diseases (CSTP, 2004). After
that decision, a task force was subse-
quently established to develop guidelines
to govern such research. This group pub-
lished its recommendations for lifting
the moratorium in 2008, after more than
3 years of discussion. The entire process,
from the first discussions of human
cloning to the final decision to lift the
prohibition on human SCNT for research
purposes, took nearly 10 years, and at
the time of this writing, no applications
have been submitted for authorization to
perform experiments involving human
embryo cloning.
Human Embryonic Stem
Cell Guidelines
The first derivation of human embryonic
stem cells (Thomson et al., 1998), just 2
years after the first report of mammalian
cloning from somatic cells, triggered
urgent discussions worldwide regarding
the justifiability of the use of early-stage
human embryos in scientific research.
The CST Bioethics Committee organized
a subcommittee to focus on research
with human embryos, which presented
the Prime Minister with recommendations
that served as the basis for governmental
guidelines on hESC derivation and use es-
tablished by the Ministry of Education,
Culture, Sports, Science, and Technology
(MEXT) in 2001 (MEXT, 2001). These
guidelines set forth standards for the deri-
vation of hESCs, including regulations on
the donation and use of human embryos
and the domestic distribution (but notell 6, May 7, 2010 ª2010 Elsevier Inc. 415
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ments for institutions and research proj-
ects. The stipulation that all research pro-
tocols involving hESCs and so-called
‘‘specified embryos’’ were required to
undergo two stages of review, at the insti-
tutional and ministry levels, was particu-
larly burdensome because it required
new approvals for even minor changes
to an approved protocol.
In 2003, a new committee was con-
vened and charged with reviewing
Japan’s guidelines and revising them in
light of advances in the field. These revi-
sions were intended to establish a system
for the distribution of newly derived Japa-
nese hESC lines, domestically and, for the
first time, internationally; to clarify training
requirements; to rationalize the handling
of cells differentiated from hESCs; and
to simplify the review of research proto-
cols. Despite the urgency expressed by
researchers, however, the revised guide-
lines were not published until 2007
(MEXT, 2007).
The most recent revisions to the hESC
guidelines came about in response to a
call for the simplification of various pro-
cedures by a cabinet panel on bioethics
in late 2008, which recommended that
the guidelines on the derivation and use
of hESCs should be divided into two
sets, one to govern derivation and dis-
tribution, and the other to govern utiliza-
tion; an amendment reflecting these pro-
posals was published in mid-2009. Major
accomplishments of this revision include
the elimination of the ministry level
review for plans to use hESCs in research,
although a two-stage review process
remains in place for hESC derivation.
In the 8 year period from the first set
of guidelines to the release of the
most recent amendment in 2009, only 58
research protocols submitted for review
have been approved. A number of pro-
minent scientists have publicly criticized
MEXT’s handling of hESC regulations
(Nakatsuji, 2007), citing the excessively
burdensome approvals process (which
was partially ameliorated in the 2008
amendments).
Germ Cell Differentiation
Similar to the case for the creation of
human embryos for research purposes
by somatic cell nuclear transfer, the deri-
vation of germ lineage cells (gametes
and their precursors) from pluripotent416 Cell Stem Cell 6, May 7, 2010 ª2010 Elsstem cells has been prohibited for a
lengthy period under Japan’s stem cell
research policies. The 2001 guidelines
on the derivation and use of hESCs
banned the creation of human individuals
by implanting an embryo generated from
hESCs into a uterus, the introduction of
hESCs into a human embryo or fetus,
and the production of germ cells from
hESCs. It was not until 2005 that discus-
sions were held on revising these prohibi-
tions to allow for the differentiation of
germ cells from hESCs for certain types
of experiment, such as the production of
recipient oocytes for use in SCNT.
A task force was subsequently con-
vened to study the issue, and in 2008 pub-
lished its recommendations that germ
cell differentiation research protocols
should be permitted only for purposes of
research into mechanisms of develop-
ment and regeneration or for the develop-
ment of diagnostic, preventive, or regen-
erative medical procedures or products,
but that fertilization via gametes derived
from human pluripotent stem cells was
prohibited (MEXT, 2008). This task force
is currently drawing up guidelines to
reflect these conclusions, and a draft
was presented at a CSTP meeting in early
2010, but at the time of this writing, they
have yet to be published.
Somatic Stem Cells and Clinical
Research
Although hematopoietic stem cells have
been used in clinical applications for
decades, for much of this time there
were no specific governmental regula-
tions on clinical research with somatic
stem cells, leading to concerns that
this may have made it possible for inap-
propriate experimental or nonefficacious
clinical protocols to be implemented. In
response to the demands of this rapidly
evolving field, the Ministry of Health,
Labor, and Welfare (MHLW) organized
an expert committee on clinical research
with human stem cells in 2001. Its discus-
sion focused on three key questions: the
limits of clinical application, systems for
evaluating clinical research with somatic
stem cells, and issues surrounding the
harvesting, processing, transplantation,
and monitoring of stem cells and their
derivatives. After these deliberations,
guidelines focused on the maintenance
of safety and determination of efficacy,
ethical conduct, informed consent forevier Inc.donors and patients, quality assurance,
transparency, and protection of privacy
were published in 2006 (MHLW, 2006).
These guidelines also call for a two-tiered
review system, by the institutional review
board and governmental committee. As
of February 2010, 36 research applica-
tions had been submitted, 24 of which
were approved. Here again, the process
from convening of the expert committee
to the publication of the guidelines
required 5 years.
Impacts on Stem Cell Research
As outlined above, the development of
governmental policy and regulatory posi-
tions (in the form of recommendations,
guidelines, and laws, etc.) on multiple
aspects of stem cell research, including
the derivation and use of hESCs, the crea-
tion of human embryos by SCNT, the
differentiation of germ cells from pluripo-
tent stem cells, and the conduct of clinical
studies, has involved lengthy periods of
discussion, preparation, review, and revi-
sion. Indeed, the time from the establish-
ment of the initial committee or task force
to the enactment of the relevant regula-
tions in their current forms has required
between 5 and 10 years in each case.
Although direct, quantitative effects are
difficult to demonstrate, it seems reason-
able that these regulatory delays have
presented serious challenges to Japa-
nese researchers working, or seeking
to work, in these fields, and ultimately
impeded progress and competitiveness
(Levine, 2008).
Human embryonic stem cell derivation
and use provides one good example.
Despite its demonstrated strengths in
the closely related field of mouse embry-
onic stem cell research, Japan was a
comparatively minor player in the deriva-
tion of new hESC lines during the years
from 1998 to 2005, when the majority of
extant hESC lines were established.
During this period, scientists from a single
Japanese lab succeeded in deriving only
three hESC lines (Suemori et al., 2006)
(an additional two lines were established
by the same group in 2008). This com-
pares unfavorably with the output of
numerous smaller countries with more
limited funding for stem cell research,
such as Belgium, Korea, the Czech
Republic, Israel, Turkey, and Taiwan
(hESCreg, 2010). This inhibition of produc-
tivity was compounded by the lack of
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tribution of Japanese hESC lines until
the publication of amended guidelines in
late 2008, resulting inevitably in impacts
on the ability of Japanese researchers to
pursue collaborations outside of Japan.
Somatic cell nuclear transfer is a sec-
ond field in which Japan has an impres-
sive record of achievement in model
organisms, including mouse, cow, pig,
and, recently, nonhuman primate, but in
which, presumably resulting in part from
dilatory regulatory developments, it has
failed to compete in human studies. The
moratorium on human SCNT imposed in
2001 prevented even the submission of
a research protocol for review until its
lifting in 2009, and there have been no
such submissions in the year subsequent
to the publication of the amended guide-
lines. The experience has been similar
in germline differentiation and clinically
oriented studies—limitations on human
research have caused Japanese scien-
tists to restrict themselves to animal
studies.
International Context
The Japanese experience in the develop-
ment and implementation of its stem cell
regulations provides valuable lessons on
policy setting in rapidly advancing or con-
troversial fields of biomedical research.
A number of aspects of the regulatory
activities described above are particularly
striking. First of these is that the Japanese
bureaucracy moved more slowly than
counterparts in other nations, Singapore
being a good example (Colman, 2008),
especially in centralized governments
not confronted with religious or political
debates. This contrast may be due
to the consensus-building nature of
Japanese decision making. For example,
the first committee to focus on hESC
research and the generation of human
blastocysts for research purposes with
SCNTwas delayed by an inability to reach
consensus after nearly 2 years of discus-
sions; this deadlock was broken only by
adopting the majority position, unusual
in a country where it is more typical for
both sides to compromise so as to reach
a unanimous agreement. Initial delays
were further compounded by the frequent
revision of existing guidelines, creating a
climate of uncertainty surrounding many
areas of stem cell research involving the
use of human materials.These delays were compounded in
particular by the extremely limited sour-
ces of funding for basic research in Japan.
In the United States, the scientific com-
munity was able to locate significant alter-
native funding sources for hESC research
after restrictions were placed on federal
funds under the Bush administration
by turning to state governments, private
philanthropies, and research funds sup-
portive of such research. Japanese scien-
tists have few such options, which may
further compound their unwillingness
to bypass ministry guidelines, which as
mentioned above, do not have the force
of law.
As we can see from these examples, in
the first decade of its regulatory approach
to stem cell research (with human mate-
rials in particular), Japan was unable to
take advantage of either the capacity for
rapid decision making of a fully central-
ized approach (such as seen in several
other countries in Asia) or the diversity of
support structures inherent in pluralist
systems, such as the United States.
Both centralized and pluralistic systems
have their advantages and potential
pitfalls; the Japanese experience, how-
ever, highlights the risks of the middle
ground. This example may serve as
a lesson to scientists and policymakers
in Asian nations that are beginning to
move toward greater pluralism, and for
those in Western nations that may look
with envy on the ability of centralized
governments to act swiftly and unilaterally
in their support of a prioritized field.
It could further be argued that scien-
tists, as a body of primary stakeholders,
have failed to work sufficiently closely
with policy-setting institutions. Although
multiple leading researchers are invited
to comment on and help steer such
decisions individually, this participation
tends to be only at the request of the
government, and independent, coordi-
nated engagement in the form of advo-
cacy and public understanding of science
activities remains the exception, rather
than the rule. The effects of this lack of
external advocacy are compounded by
the lack of expertise with the ministries,
which tend to be staffed by lifetime
bureaucrats who rotate positions every
few years. In contrast to, and perhaps as
a consequence of, this mobility, however,
rules tend to suffer entrenchment. These
deficits in participation by the researchCell Stem Ccommunity and dedicated expertise
within the bureaucracy may have
undercut some of these advantages
Japan created for itself in adopting early
and proactive positions to the regulation
of many areas of stem cell research.
We would, in closing, like to emphasize
that despite these handicaps, Japan
remains one of the leading nations in
stem cell research, as highlighted by its
development of such breakthrough tech-
nologies as induced pluripotent stem cells
(Takahashi and Yamanaka, 2006; Taka-
hashi et al., 2007). We suggest that efforts
to reform and rationalize existing regula-
tory mechanisms would facilitate the
development of more appropriate and
balanced regulations aligned to the soci-
etal and cultural norms of the Japanese
people and capable of driving the nation’s
already powerful stem cell research com-
munity to even greater achievements.
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